MTPS 9579A
Alternative Names: MTPS-9579A; RG-6173Latest Information Update: 05 Nov 2023
At a glance
- Originator Genentech
- Class Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Tryptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Chronic urticaria
Most Recent Events
- 04 Sep 2022 Efficacy and pharmacokinetic data from a phase I trial in Asthma presented at the 32nd Annual Congress of the European Respiratory Society (ERS-2022)
- 22 Aug 2022 Discontinued - Phase-II for Chronic-urticaria in USA (IV)
- 12 Aug 2022 Genentech withdrew a phase II trial before enrollment in Chronic-urticaria in USA (IV), as the development of RG 6173 was terminated for strategic/business reasons (NCT05129423) (EudraCT2021-002669-16)